Dw. Sternberg et al., The TEL/PDGF beta R fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways, BLOOD, 98(12), 2001, pp. 3390-3397
The TEL/PDGF betaR gene, which encodes a fusion protein containing the ETS-
family member TEL fused to the protein-tyrosine kinase domain of the platel
et-derived growth factor receptor-beta (PDGF betaR), confers interleukin 3
(IL-3)-independent growth on Ba/F3 hematopoietic cells. TEL/ PDGF betaR mut
ants have been generated that contain tyrosine-to-phenylalanine (Tyr-->Phe)
substitutions at phosphorylation sites present in the native PDGF betaR to
assess the role of these sites in cell transformation by TEL/PDGF betaR. S
imilar to previous findings in a murine bone marrow transplantation model,
full transformation of Ba/F3 cells to IL-3-independent survival and prolife
ration required the TEL/PDGF betaR juxtamembrane and carboxy terminal phosp
horylation sites. In contrast to previous reports concerning comparable mut
ants in the native PDGF betaR, each of the TEL/PDGF betaR mutants is fully
active as a protein-tyrosine kinase. Expression of the TEL/PDGF betaR fusio
n protein causes hyperphosphorylation and activation of signal transducer a
nd activator of transcription (STAT5), and this activation of STAT5 require
s the juxtamembrane Tyr579 and Tyr581 in the TED/PDGF betaR fusion. Hyperph
osphosphorylation of phospholipase C gamma (PLC gamma) and the p85 subunit
of phosphatidylinositol 3-kinase (PI3K) requires the carboxy terminal tyros
ine residues of TEL/PDGF betaR. Thus, full transformation of Ba/F3 cells by
TEL/ PDGF betaR requires engagement of PI3K and PLC gamma and activation o
f STAT5. Taken together with the growth properties of cells transformed by
the TEL/PDGF betaR variants, these findings indicate that a minimal combina
tion of these signaling intermediates contributes to hematopoietic transfor
mation by the wild-type TEL/PDGF betaR fusion. (Blood. 2001;98:3390-3397) (
C) 2001 by The American Society of Hematology.